Over a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of N...

India's obesity treatment market is set for a major shift by year-end. A wave of oral GLP1 weight-loss pills, including those from China, w...

Pharma major Lupin has launched its generic anti-diabetic medicine in the United States. The medicine is dapagliflozin and metformin hydroc...

Lupin, an Indian drug maker, partners with SteinCares. The agreement focuses on ranibizumab's commercialisation. Latin America, excluding M...

Lupin Share Price: Lupin has acquired the anti-diabetes trademarks GIBTULIO, GIBTULIO MET, and AJADUO from Boehringer Ingelheim to bolster ...

IMS values the Indian diabetes market is at Rs9,003 crore and has recorded it as growing at 19.5%, according to a release by Lupin.

Lupin has launched 10 products in the US this fiscal year and has received approvals for 21 from the FDA. The drug maker has 35 FTF product...

The Kolkata Patent Office, on an opposition filed by domestic drug firm Lupin, refused the patent application on grounds that it was "obvio...

Boehringer Ingelheim will continue to sell its linagliptin under the brand names Trajenta (monotherapy) and TrajentaDuo (fixed-dose combina...

As per the strategic distribution pact inked between the two companies, Mumbai-based Lupin will launch LG Life Sciences' Insulin Glargine.

"Lupin's Pioglitazone tablets is to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings," the co...

Lupin has received US health regulator's approval to sell its generic version of Glumetza HCl ER Tablets in US market.

In the wake of a government ban on top-selling diabetes drug, pioglitazone , the volumes are expected to shift to other classes such as fir...

Lupin today said it has reached a patent litigation settlement agreement with US-based firms Santarus Inc and Depomed Inc involving diabete...

Lupin today said it has received approval from the US health regulator for its Metformin Hydrochloride Extended Release tablets, used in tr...

Danish company Novo Nordisk has sued Mumbai-based drugmaker Lupin to prevent it from launching the low priced version of its patented diabe...

Antibiotics and speciality domestic pharma major Lupin is planning to diversify into new therapeutic segments.